Searched for
ERIS PHARMA
Ipca Laboratories among 5 stocks showing bullish RSI upswingFive Nifty500 stocks, including Leela Palaces, Eris Lifesciences, Indian Bank, Mankind Pharma, and Ipca Laboratories, showed bullish moment...- Dividend alert! Last date to buy Bajaj Auto, GSK Pharma and 10 other stocks for solid payouts. Details hereTwelve companies are set to go ex-dividend on Friday, offering shareholders payouts totaling over Rs 250. Bajaj Auto leads with a Rs 150 pe...
- Dividends, bonus issues: TCS, LIC, Bajaj Auto among 30 stocks turning ex-date this week. Check detailsInvestors must hold shares of these companies in their demat accounts on the record date to be eligible for the respective corporate action...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
- Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
- Rs 12,000 crore magic pill race begins to shrink India's pot bellies. Which pharma stocks will win GLP-1 war?India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...
- Price alone won't push weight-loss, diabetes drug semaglutide sales: DoctorsLeading drugmakers including Sun Pharmaceuticals, Dr Reddy’s Laboratories, Zydus Lifesciences, Natco Pharma, Eris Lifesciences, USV, Glenma...
- Natco Pharma, Eris Lifesciences shares jump up to 6% on partnership for Semaglutide launch in IndiaShares of Natco Pharma and Eris Lifesciences climbed on Tuesday after announcing a partnership to commercialise Semaglutide in India. Natco...
- Eris Lifesciences partners Natco to commercialise semaglutideEris Lifesciences has partnered with Natco Pharma to introduce semaglutide in the Indian market a cutting-edge therapy for Type 2 diabetes ...
- Eris Lifesciences eyes ‘good’ share in semaglutide generics, says COOEris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March 2026. Eris aims ...
- Eris Lifesciences to buy some dermatology brands from Glenmark PharmaThe deal, through Eris' dermatology focused unit, is for the purchase of nine brands, including Onabet, Halobate, Sorvate, and Demelan for ...
- Eris Lifesciences Q3 results: Net profit up 42% at Rs 90 croreConsolidated total revenue from operations of the company stood at Rs 310.42 crore for the quarter under consideration. It was Rs 266.39 cr...
- Accumulate Eris Lifesciences, target Rs 704: Prabhudas LilladherAccumulate Eris Lifesciences Ltd. at a price target of Rs 704.
- Eris Lifesciences IPO sails through; oversubscribed 3 timesThe public offer received bids for 1.34 crore shares against the total issue size of 1.59 crore shares.
- Eris Lifesciences IPO subscribed 75% on Day 2The price band for the share sale has been fixed at Rs 600-603.
- Should you invest in Eris Lifesciences?Despite being expensive, the issue holds a compelling investment proposition.
- Eris Lifesciences sets IPO price band in Rs 600-603 rangeThe shareholders of the company plans to sell 28,875,000 equity shares.
- Pharma salesman’s company Eris Lifesciences eyes Rs 10,000-crore tag in IPOIndian pharma's first sales professional-turned-entrepreneur, the 41-year-old Amit Bakshi, has hired bankers for the IPO of Eris Lifescienc...
- Aurobindo divests Australian arm to Eris PharmaAPL will continue to manufacture and supply products to Eris Pharma for Australian and New Zealand markets over the next few years.
Load More
